Anti-Fas (CD95) (Human) mAb (Monoclonal Antibody)
Fas Monoclonal Antibody.
Specifications:
Description
Monoclonal Antibody of 100 μg targeting Fas for FCM, NT, WB.
| Target: | Fas |
|---|---|
| Product Type: | Antibody |
| Size: | 100 μg |
| Application: | FCM, NT, WB |
| Research Area / Disease: | Apoptosis |
| Conjugate: | Unlabeled |
| Antibody Type: | Monoclonal |
| Clone Number: | ZB4 |
| Concentration: | 1 mg/mL |
| Formulation: | 100 μg IgG in 100 μl volume of PBS containing 1% BSA and 0.09% NaN3. |
| Isotype: | IgG1 |
| Immunogen: | Recombinant human Fas |
| Host Species: | Mouse |
| Species Reactivity: | Human |
| Source: | This antibody was purified from hybridoma(clone ZB4) supernatant using protein A agarose. Thishybridoma was established by fusion of mouse myelomacell NS-1 with Balb/c mouse splenocyte immunized withrecombinant human Fas. |
| Reactivity: | This antibody reacts with human Fas onWestern blotting and Flow cytomet ry. It does not react withmouse Fas. |
| Gene ID Human: | |
| Gene ID Mouse: | |
| Storage Temperature: | '-20°C |
| Regulatory Statement: | For Research Use Only. Not for use in diagnostic procedures. |
Citations
- Chiou SH, et al., The immediate early 2 protein of human cytomegalovirus (HCMV) mediates the apoptotic control in HCMV retinitis through up-regulation of the cellular FLICE-inhibitory protein expression. J Immunol. 177:6199-206. 2006,
- Chiou SH, et al., Up-regulation of Fas ligand expression by human cytomegalovirus immediate-early gene product 2: a novel mechanism in cytomegalovirus-induced apoptosis in human retina. J Immunol. 167:4098-103. 2001,
- Zanin-Zhorov A, et al., Fibronectin-associated Fas ligand rapidly induces opposing and time-dependent effects on the activation and apoptosis of T cells. J Immunol. 171:5882-9. 2003
- Jing ZT et al. Hepatitis B Virus Surface Antigen Enhances the Sensitivity of Hepatocytes to Fas-Mediated Apoptosis via Suppression of AKT Phosphorylation. J Immunol. 201, 2303-2314 (2018)
References
- Arokium, H., et al., J. Virol. 83, 11283-11297 (2009)
- Giammarioli, A. M., et al., Cancer Res. 68, 5291-5300 (2008)
- Schumann, D. M., et al., PNAS 104, 2861-2866 (2007)
- Maedler, K., et al., Diabetes 55, 2713-2722 (2006)
- Gilhar, A., et al., Am. J. Pathol. 168, 170-175 (2006)
- Ito, K., et al., Cancer Res. 65, 4417-4424 (2005)
- Ahmed, F., et al., Blood 103, 2079-2087 (2004)
- Holler, N., et al., Mol. Cell. Biol. 23, 1428- 1440 (2003)
- Maedler, K., et al., PNAS 99, 8236-8241 (2002)
- Maedler, K., et al., Diabetes 50, 1683-1690 (2001)
- Jiang, S., et al., Invest. Ophthalmol. Vis. Sci. 41, 645-655 (2000)
- Landowski, T. H., et al., Blood 94, 265-274 (1999)
- Agrawal, S., et al., J. Clin. Invest. 102, 1715-1723 (1998)
- Giordano, C. et al., Science 275, 960-963 (1997)
- Boirivant, M., et al., J. Clin. Invest. 98, 2616-2622 (1996)
